The U.S. Food and Drug Administration today approved Fragmin (dalteparin sodium) injection, for subcutaneous use, to reduce the recurrence of symptomatic venous thromboembolism (VTE) in pediatric patients...

An international clinical trial has found that a new drug for Huntington’s disease is safe, and that treatment with the drug successfully lowers levels of the abnormal protein that causes the debilitating...

Travelers to many parts of the world are at risk for contracting malaria, According to the Centers for Disease Control and Prevention (CDC), approximately 1,700 cases occur each year among international...

The U.S. Food and Drug Administration today approved Mavyret (glecaprevir and pibrentasvir) tablets to treat all six genotypes of hepatitis C virus (HCV) in children ages 12 to 17. Mavyret was previously...

The U.S. Food and Drug Administration Friday granted final approval of the first generic naloxone hydrochloride nasal spray, commonly known as Narcan, a life-saving medication that can stop or reverse...

Prescribing prolonged courses of antibiotics for patients experiencing symptoms attributed to Lyme disease can lead to harmful health outcomes, says a new position paper by Canada’s infectious disease...

The United States faces a converging public health crisis as the nation’s opioid epidemic fuels growing rates of certain infectious diseases, including HIV/AIDS, hepatitis, heart infections, and skin...

A new strategy to combat antibiotic resistance has emerged from a study led by researchers at Baylor College of Medicine. Published in the journal Molecular Cell, the report reveals for the first time...

CDC is issuing new guidance to clinicians for the treatment of severe malaria cases in the United States (U.S.). This change in treatment protocol is necessary because the only FDA-approved intravenous...

The U.S. Food and Drug Administration today approved Mayzent (siponimod) tablets to treat adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting...